Translational Aspects of Epithelioid Sarcoma: Current Consensus

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Epithelioid sarcoma (EpS) is an ultra-rare soft-tissue cancer primarily affecting young adults.
• EpS has a poor prognosis, with a ~50% fatality rate despite aggressive multimodal treatments.
• Loss of INI1 expression due to SMARCB1 gene deletion characterizes EpS subtypes.

Purpose of the Study:

• To review the current understanding of EpS from a translational research perspective.
• To identify innovative research directions for EpS diagnosis and treatment.
• To address critical questions defined by expert consensus and patient advocacy.

Main Methods:

• Literature review and expert consensus from international EpS meetings (2021, 2023).
• Analysis of current therapeutic strategies and their limitations.
• Identification of knowledge gaps in EpS biology and treatment.

Main Results:

• Tazemetostat, an EZH2 inhibitor, was the first targeted therapy approved for EpS but benefits a minority of patients.
• Immunotherapy and other novel treatments show efficacy in only a fraction of EpS cases.
• Significant unmet needs exist for effective, EpS-specific diagnostic tools and therapies.

Conclusions:

• Novel, EpS-specific therapeutic strategies are urgently required.
• Accelerating translational research is crucial for developing new treatments.
• Continued collaboration among researchers, clinicians, and patient groups is vital for advancing EpS care.